NCT07096999招募中不适用
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Response and toxicity following 177Lu-RLT
研究概览
简要总结
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •* 177Lu-617 PSMA treatment scheduled for mCRPC
- •Clinically stable as determined by the nuclear medicine clinicians
- •≥ 18 years of age
- •Willing and able to provide informed consent
排除标准
- •Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed
结局指标
主要结局
Response and toxicity following 177Lu-RLT
时间窗: Up to 4 years
Association between absorbed dose and effect (response/toxicity) following 177Lu-RLT
次要结局
- Build and test models(Up to 4 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate CancerNCT05613738Peking Union Medical College Hospital9
已完成
不适用
RAD327 Lu-177 Dosimetry with SPECT/CTneuroendocrine tumorsC80C17C25.9Malignant neoplasm, without specification of siteMalignant neoplasm of small intestinePancreas, unspecifiedDRKS00011489niversitätsklinikum Magdeburg6
招募中
不适用
Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)Metastatic Castration-resistant Prostate CancerNCT05823402BAMF Health30
撤回
2 期
PSMA-PET/MRI Low- and Intermediate-Risk Prostate CancerProstate CancerNCT04243941UNC Lineberger Comprehensive Cancer Center
Unknown
2 期
177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate CancerMetastatic Castration-resistant Prostate CancerNCT04188587Nanjing First Hospital, Nanjing Medical University30